Key facts
- It has raised $4.1M across 1 recorded rounds; the latest was Seed Round ($3.3M) in Dec 2021.
- Notable investors include Creative Destruction Lab, Viking Global Investors, Federal Economic Development Agency for Southern Ontario, BioMedPartners, CCRM Enterprises — 13 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Mediphage
Funding rounds
1 roundsAbout Mediphage
Operator of a biotech company intended to specialize in non-viral gene delivery. The company's proprietary core technology, ministring DNA (msDNA), is a novel gene delivery vector to overcome challenges faced by viral gene therapies, leveraging the versatility for genetic and infectious diseases with limited or no treatment options available, enabling medical researchers to overcome the limitations of current viral vector-based gene therapy technologies.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Toronto, Canada
- Founded
- 2016
- Employees
- 17
- Website
- mediphage.ca/
- Ownership
- Privately Held (backing)
Mediphage doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mediphage shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mediphage in its N-PORT filings yet. We sweep new filings monthly.